Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 16, 1, 3, 105 and 18 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Abliva AB
AegisCN LLC
AivoCode LLP
AlphaCognition Inc
ALSP Inc
AlzeCure Pharma AB
American CryoStem Corp
Amgen Inc
Anagin Inc
Angion Biomedica Corp
Anida Pharma Inc
Annovis Bio Inc
AntiRadical Therapeutics LLC
Aptinyx Inc
Astrocyte Pharmaceuticals Inc
Astrogen Ltd
Athersys Inc
Avanir Pharmaceuticals Inc
B Cell Solutions Inc
Bessor Pharma LLC
Beyond Barriers Therapeutics Inc
Biogen Inc
BioIncept LLC
Bioquark Inc
Biosplice Therapeutics Inc
Brain-Gen LLC
Braxia Scientific Corp
CalciMedica Inc
Calico Life Sciences LLC
CavoGene LifeSciences
CellCure
Cellvation Inc
CereSpir Inc
Chimerix Inc
Chrysalis BioTherapeutics Inc
Claritas Pharmaceuticals Inc
Cognosci Inc
Complement Pharma BV
Covis Pharmaceuticals Inc
Deha Pharmaceutical LLC
Eagle Pharmaceuticals Inc
Eisai Co Ltd
Emerald Organic Products Inc
Epigen Biosciences Inc
Expesicor Inc
Fortuna Fix Inc
GABA Therapeutics Inc
GNT Pharma Co Ltd
Gryphon Therapeutics Inc
Hemarina SA
Hibernaid Inc
Hillhurst Biopharmaceuticals Inc
Hope Biosciences LLC
Hopstem Biotechnology LLC
Hoverink Biotechnologies Inc
ImmunoChem Therapeutics LLC
Inflammatory Response Research Inc
International Stem Cell Corp
Ischemix Inc
JT Pharmaceuticals Inc
Jupiter Neurosciences Inc
Levolta Pharmaceuticals Inc
M et P Pharma AG
Mapreg SAS
Mercaptor Discoveries Inc
NervGen Pharma Corp
NeuExcell Therapeutics Inc
NeurAegis Inc
Neuren Pharmaceuticals Ltd
NeurExo Sciences LLC
Neurodon LLC
Neuronasal LLC
NeuroNascent Inc
Neuropathix Inc
Neuroplast BV
NeuroTheranostics Inc
NeuroTrauma Sciences LLC
New World Laboratories Inc
NoNO Inc
Noveome Biotherapeutics Inc
NuvOx Pharma LLC
Nyrada Inc
Odyssey Health Inc
OncoSynergy Inc
Orpheris Inc
Oxeia Biopharmaceuticals Inc
Palisade Bio, Inc
Peptron Inc
Personalized Stem Cells Inc
PharmaTher Holdings Ltd
PharmatrophiX Inc
Pinteon Therapeutics Inc
Praetego Inc
ProNeurogen Inc
ProThera Biologics Inc
Protheragen Inc
PurMinds NeuroPharma Inc
Qrons Inc
RegeneRx Biopharmaceuticals Inc
Resolys Bio Inc
Revalesio Corp
Revive Therapeutics Ltd
RHNanopharmacuticals LLC
Rubicon Biotechnology Inc
Samus Therapeutics Inc
SanBio Co Ltd
SciSparc Ltd
Shinkei Therapeutics LLC
Silver Creek Pharmaceuticals Inc
SL Bigen Co Ltd
Spinogenix Inc
STATegics Inc
Stemedica Cell Technologies Inc
Swedish Orphan Biovitrum AB
Synaptogenix Inc
Takeda Pharmaceutical Co Ltd
Tetra Therapeutics
Thera Neuropharma Inc
Therapeutic Solutions International Inc
Theratome Bio Inc
TikoMed AB
Trigemina Inc
vasopharm GmbH
Ventus Therapeutics Inc
VG Life Sciences Inc
Virogenomics BioDevelopment Inc
Vitro Diagnostics Inc
Vivazome Therapeutics Pty Ltd
Wesana Health
Xonovo Inc
ZyVersa Therapeutics Inc